Background: Desired serotonin 5HT2 receptor pharmacology for treatment of psychoses is 5HT2A antagonism and/or 5HT2C agonism. No selective 5HT2A antagonist has been approved for psychosis and the only approved 5HT2C agonist (for obesity) also activates 5HT2A and 5HT2B receptors, which can lead to clinical complications. Studies herein tested the hypothesis that a dual-function 5HT2A antagonist/ 5HT2C agonist that does not activate 5HT2B receptors would be suitable for development as an antipsychotic drug, without liability for weight gain.
Introduction
Brain dopamine and serotonin systems have long been thought to be involved in the pathophysiology and pharmacotherapy of schizophrenia and other psychoses. For example, the dopamine hypothesis of schizophrenia arose from observations that the first relatively safe and effective antipsychotic drugs, the phenothiazines (e.g., chlorpromazine) in the early 1950s, affect brain dopamine metabolism (Carlsson and Lindquist, 1963) . Neuroleptics such as chlorpromazine and the butyrophenone haloperidol "take hold" (lepsis) of the central nervous system (CNS) to suppress movement as well as other behavior, and resulting debilitating extrapyramidal movement side effects are implicit in the clinical definition of neuroleptic antipsychotic drugs. Newer antipsychotic drugs, without substantial risk of extrapyramidal effects, are referred to as "atypical" and have a mechanism other than (or in addition to) postsynaptic D2-type receptor blockade. Such second generation antipsychotics include the dibenzodiazepines (e.g., clozapine, olanzapine) that have less potential for extrapyramidal side effects and have significant activity at brain serotonin 5HT2-type receptors (as well as adrenergic a1/a2, muscarinic, and/or histamine H1 receptors) in addition to activity at D2-type receptors (Meltzer, 1996; Meltzer et al., 2003; Seeman, 2002; Tandon and Fleischhacker, 2005) . Speculatively, a relatively selective 5HT2A antagonist might function as a useful antipsychotic medication. Several new potential medications have been developed as antipsychotic drugs that are selective 5HT2A antagonists/inverse agonists, however little success in the clinic has been observed (clinicaltrials.gov reveals no ongoing trials using selective 5HT2A compounds) suggesting that selective blockade of 5HT2A alone may not represent the ideal pharmacological profile.
One side effect of atypical antipsychotics is weight gain (Coccurello and Moles, 2010; Lieberman et al., 2005; Maayan and Correll, 2010; McCloughen and Foster, 2011) . In addition to H1 antagonism (Kroeze et al., 2003) , it has been proposed that the weight gain effects of many atypical antipsychotic drugs are due to concurrent antagonism of the 5HT2C receptor along with the 5HT2A receptor (Balt et al., 2011; Kirk et al., 2009; Meltzer and Massey, 2011; Roerig et al., 2011) . In fact, most atypical antipsychotic drugs that are 5HT2A antagonists/inverse agonists are also 5HT2C receptor antagonists/inverse agonists (Herrick-Davis et al., 2000; Rauser et al., 2001) . Preclinical data suggest that activation of 5HT2C receptors is associated with decreased eating and weight loss (Hayashi et al., 2005; Hewitt et al., 2002; Rowland et al., 2008) . In addition, one neuropharmacological consequence of 5HT2C activation is preferential decreases in mesolimbic compared to nigrostriatal dopamine levels (Di Giovanni et al., 2000; Marquis et al., 2007) which may suggest an improved antipsychotic effect without motor-related side effects. Thus, the desirable serotonergic pharmacology for an antipsychotic medication is 5HT2A antagonism and 5HT2C agonism. It should be noted that there is no clinical tolerance for activation of 5HT2B receptors as this is associated with severe cardiac valvulopathy and other cardiotoxic effects (Elangbam, 2010; Roth, 2007) .
We previously reported that a novel phenylaminotetralin, (À)-(2S, 4R)-trans-4-phenyl-N,N-dimethyl-2-aminotetralin (PAT; Fig. 1 ), was a 5HT2C agonist with 5HT2A and 5HT2B inverse agonist/ antagonist activity ) that demonstrated preclinical antipsychotic activity and decreased intake of a highly palatable food in non-food-deprived mice (a binge eating model) . The PAT molecular scaffold ( Fig. 1) has two chiral centers, thus, there are a pair of cis-and trans-enantiomers, for a total of four stereoisomers. For PAT, the (À)-(2S, 4R)-trans enantiomer is most potent and efficacious regarding binding and function across 5HT2 receptor subtypes ). Here we report on two novel analogs that contain a chlorine moiety at 4 0 -or para-position of the pendant C(4) phenyl group on the PAT parent compound, (þ)-(2R, 4S)-and (À)-(2S, 4R)-trans-4-(4 0 -chlorophenyl)-N,N-dimethyl-2-aminotetralin (p-Cl-PAT; Fig. 1 ). Computational chemistry studies suggest that the electronegative chlorine atom at the para-position of the PAT phenyl ring provides an electronic and steric symmetry that modulates affinity and function at 5HT2 receptors , 2012 . Here we report the in vitro 5HT2 affinity and function of (þ)-and (À)-p-Cl-PAT and assess its in vivo 5HT2 activity after intraperitoneal (i.p.) and oral (p.o.) administration in behavioral paradigms sensitive to the antipsychotic and "anti-binge-eating" effects of potential therapeutics.
Methods

Chemicals
The radioligands [ (Morgan et al., 2012) and a full description of the methods and physical characterization will be reported elsewhere. Briefly, 4-(4 0 -chlorophenyl)-tetralen-2-ol phenylacetate was synthesized from 4-chlorostyrene and trifluoroacetyl phenylacetyl anhydride via cascade FriedeleCrafts cycli-acylalkylation, enolization, and O-acylation following our published procedures (Vincek and Booth, 2009 ). The tetralen-2-ol phenylacetate was reduced with sodium borohydride at 50 C in methanol to yield the cis-tetralol (major) that was converted to the corresponding cis-tosylate using p-tosyl chloride in pyridine at room temperature. The cis-tosylate on amination with aqueous dimethylamine solution in a sealed tube at 80 C for 24 h yielded racemic trans-4- 
Clonal cell culture and transfection
Human embryonic kidney 293 cells (HEK, ATCC CRL-1573) were maintained in Dulbecco's modified Eagle's medium (DMEM) with 5% fetal bovine serum and 1% penicillinestreptomycin. Cells were grown in a humidified incubator at 37 C with 5% carbon dioxide. The cDNAs encoding the human 5HT2A, 5HT2B and 5HT2C INI (unedited wild type isoform) wild type receptors were obtained from UMR cDNA Resource Center (Rolla, MO). HEK-293 cells were grown to 90% confluency in DMEM (10-013-CV, Mediatech, Manassas, VA), supplemented with 5% dialyzed fetal bovine serum in 10 cm plates. Cells were washed then transfected with 24 mg of 5HT2 receptor subtype cDNA mixed with 40 mL Lipofectamine 2000 reagent in Opti-MEM and placed in an incubator for 24e48 h. Membranes were then collected in 50 mM Tris, 10 mM MgCl 2 e6H 2 O, and 0.1 mM EDTA (assay buffer) using previous methods ) and stored at À80 C until binding assays were performed.
2.3. In vitro molecular pharmacology 2.3.1. Radioreceptor competition binding assays Radioligand competitive displacement binding assays were performed in 96-well plates, using 3e5 mg of protein from membrane samples per well, similar to laboratory methods used previously ]-radioligand were dried, placed in vials containing 2 mL scintillation cocktail (ScintiVerse), allowed to equilibrate overnight, and then were counted for 3 H-induced scintillation using a Beckman-Coulter LS6500 counter. Binding experimental conditions were performed in triplicates, and each experiment was performed a minimum of three times. Data were analyzed using nonlinear regression curve-fitting algorithms in GraphPad Prism, 5.03 for Windows (San Diego, CA). Data points were limited to eight, thus Hill slopes were not calculated (Motulsky and Christopoulos, 2003) ; data were fit using the "one site fit-K i " model that constrains the Hill slope to 1.0. Ligand affinity is expressed as K i values by conversion of the IC 50 data using the equation
where L is the concentration of radioligand (Cheng and Prusoff, 1973) . Comparisons of K i values were performed using two-way ANOVA with Bonferroni's post-hoc test. Differences were considered statistically significant when the p-value was less than 0.05. 
Measurement of PLC activation and [
Canal et al., 2011). HEK cells grown to approximately 80% confluency in DMEM containing 10% fetal bovine serum and 1% antibiotic in 10 cm plates at 37 C, 5% CO 2 (incubator) were washed one time with PBS, then transfected with 20 mg 5HT2 receptor subtype cDNA and 40 mL lipofectamine 2000 reagent in 5 mL DMEM containing 5% dialyzed fetal bovine serum and 5 mL Opti-MEM (transfection media). Cells were placed in an incubator, and approximately 16 h later, transfection media were removed and replaced with 16 mL inositol-free DMEM containing 2.5% dialyzed fetal bovine serum. Cells were then detached by vigorous pipetting, 0.1 mCi/mL [ 3 H]-myo-inositol was added to the mixture (labeling media), and cells were seeded 300 mL per well into 48 well CellBind Ò plates (Costar), and placed in an incubator. 24 h later, plates were centrifuged at 2500 rpm for 10 min at room temperature, labeling media were discarded, and 450 mL inositol-free, serum-free DMEM was added to each well. Cells were placed in an incubator for 1 h. Cells were then incubated for 30 min with the desired concentration of test compound diluted in inositol-free, serum-free DMEM containing a final concentration of 50 mM LiCl and 10 mM pargyline per well. Plates were again centrifuged at 2500 rpm for 10 min at room temperature, drug incubation media were discarded, and 400 mL of 50 mM formic acid was added to each well to lyse cells. One hour later, 200 mL of 150 mM NH 4 OH was added to each well to neutralize cells, and plates were stored at À20 C over- C57Bl/6J male mice were obtained from Harlan (food studies) or Jackson (HTR) Laboratories at approximately 8 weeks of age, and allowed to acclimate to the temperature-and humidity-controlled colony room for at least 1 week prior to testing. Mice were singly-(food studies) or pair-(HTR) housed in standard cages and allowed unlimited access to laboratory chow and water. Experiments were conducted at approximately the middle of the light phase (lights on at 6 am, and lights off at 6 pm). All compounds were dissolved in sterile saline prior to behavioral testing, and administered in a volume of 0.01 mL/g body weight. All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals, as promulgated by the National Institutes of Health, and were approved by the University of Florida's Institutional Animal Care and Use Committee.
DOI-elicited head-twitch response and locomotor activity
On the day of testing, mice were habituated to the testing room for approximately 30 min. Testing consisted of administration (i.p.) of sterile saline or a particular dose of (þ) or (À)-p-Cl-PAT. Ten minutes later, mice were administered (À)-DOI or sterile saline. Ten minutes later, mice were individually placed into a clear plexiglas chamber (17 00 Â 17 00 Â 12 00 ). Following oral administration of the PAT analog or saline, 20 min elapsed before administration of (À)-DOI. Head-twitch responses (HTRs), defined as a clear, rapid, and discrete, back and forth rotation of the head, were counted by a trained observer (A.K.) who was blind to drug treatment conditions, during a 10-min observation session. An overhead camera videotaped the session, and activity (distance traveled in cm) was analyzed and calculated by Ethovision software (Noldus Information Technology Inc.).
Palatable meal eating
Mice were tested in their home cages with Purina 5001 chow and water available at all times. Five days/week, mice were given a measured number of Fruit Crunchies (Bio-Serv, Frenchtown, NJ) in a glass beaker inside the cage. Crunchies, in 3 flavors, are purified ingredient and sweet spherical pellets approximately 190 mg and 3.5 kcal/g. Access was rapidly tapered to 30 min/day and intake was measured daily. After w2 weeks when day-to-day intake was stable, mice received the test compound by i.p. injection (2 mL/kg) 15 min before access to Crunchies. Intake was expressed as % of the baseline averaged across the previous 4 days.
Statistics
Differences in dependent measures were analyzed by 2-way ANOVA and posthoc NewmaneKeuls tests, or Student's t-test, as appropriate using commercially available statistical software (Sigmastat 3.1). Differences were considered statistically significant when the p-value was less than 0.05. ED50 values and 95% confidence limits were determined using log-linear interpolation from the descending limb of the doseeeffect curves.
Results
3.1.
In vitro molecular pharmacology of (þ) Fig. 3 shows functional activity of 5HT in comparison to (þ) and (À)-p-Cl-PAT at 5HT2A, 5HT2B and 5HT2C receptors, as measured by activation of PLC and [
Function
3 H]-IP formation. Consistent with the literature (e.g., Booth et al., 2009) , the endogenous agonist serotonin (5HT) had an EC 50 value of 106 AE 19 nM, 50 AE 10 nM and 10 AE 3 nM at 5HT2A, 5HT2B and 5HT2C receptors, respectively. Neither (þ) nor (À)-p-Cl-PAT activated 5HT2A or 5HT2B receptors, even at 10 mM concentration (125e300-times K i values summarized in Table 1 ). In contrast, both (þ) and (À)-p-Cl-PAT were partial agonists (compared to 5HT) at the 5HT2C receptor. Consistent with its higher affinity ( 3.2. In vivo behavioral pharmacology 3.2.1. Head-twitch responses When (À)-DOI was administered (preceded by a saline injection), there was a dose-dependent increase in the number of headtwitch responses (HTRs) observed during the 10-min session (Fig. 4,  left panel) . The number of head-twitches increased from an average of 1.25 following saline administration, to 6, 22, and 45 headtwitches following 0.1, 0.3, and 1.0 mg/kg (À)-DOI (F 9,28 ¼ 42.3; p < 0.001; significant increases at 0.3 and 1.0 mg/kg DOI). Both the (þ) and (À) enantiomers of p-Cl-PAT failed to alter the number of HTRs when administered with saline (range from 0 to 2.5 across doses; Fig. 4, left panel) . Subsequent experiments examined the effects of p-Cl-PAT pretreatment before administration of 1 mg/kg (À)-DOI (Fig. 4, right panel) . Both isomers produced a dosedependent attenuation of the DOI-elicited HTR such that following pretreatment with 30 mg/kg of the (þ) and (À) enantiomers, there were 3.3 and 13 responses, respectively. ANOVA (F 6,27 ¼ 15.66; p < 0.001) revealed that 10 and 30 mg/kg doses of (þ) and 30 mg/kg of (À)-p-Cl-PAT resulted in significantly lower levels of HTRs relative to saline pretreatment. The dose required to produce a 50% attenuation (ED50 value AE 95% CL) of the DOI-elicited response was 8.2 (5.4e12.4) and 20.1 (14.0e28.8) mg/kg for the (þ) and (À) enantiomers, and there was a significant difference between the dosee effect curves of (þ) and (À)-p-Cl-PAT (F 1,23 ¼ 17.49; p < 0.001). The effects of 30 mg/kg of each enantiomer and the racemic combination were assessed following oral administration (via gavage). Following oral saline administration, (À)-DOI (1.0 mg/kg) elicited an average of 37.5 HTRs (Fig. 5) . Oral administration of (þ), (À), and (AE) p-Cl-PAT (30 mg/kg) resulted in an attenuated response to DOI: 8.5, 18.25, and 13.25 HTRs respectively. Each dose combination resulted in fewer HTRs (F 3,16 ¼ 31.1; p < 0.001) relative to saline pretreatment, and there was a statistically significant difference between the (þ)-and (À)-enantiomers (p ¼ 0.038).
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Locomotor activity
During all behavioral sessions, levels of overall activity were recorded and are shown in Table 2 . Although, there appeared to be a Fig. 3 . AeC: Representative concentrationeresponse data for 5HT and (þ)-and (À)-p-Cl-PAT activation of 5HT2A, 5HT2B and 5HT2C receptors; D: Representative 5HT concentrationeresponse data at 5HT2A receptors in presence of increasing concentrations of (þ)-p-Cl-PAT.
Table 1
In vitro pharmacology: affinity and function of (þ)-and (À)-p-Cl-PAT at 5HT2A, 5HT2B and 5HT2C receptors. slight increase in activity following administration of 1.0 mg/kg (À)-DOI, there were no statistically significant differences following any drug alone, relative to saline. The highest doses of (þ) and (À) p-Cl-PAT administered as a pretreatment to 1.0 mg/kg (À)-DOI resulted in statistically significant lower levels of activity relative to saline pretreatment (p values < 0.05). Oral administration of p-Cl-PAT failed to alter locomotor activity when compared to oral saline pretreatment.
Palatable meal eating
Mice were provided 10 Fruit Crunchies daily, and ate on average, 5.2 (AE0.1) pellets during the baseline 30-min sessions and 5.0 (AE0.25) pellets following administration of vehicle. Both enantiomers produced a dose-dependent attenuation of the number of pellets consumed such that following pretreatment with 24 mg/kg of the (þ) and (À) enantiomers, eating was statistically significantly decreased to 15.9% (AE6.4) and 36.4% (AE9.1) of baseline levels, respectively ( Fig. 6 ; F 6,58 ¼ 33.6, p < 0.001). The doses required to produce a 50% attenuation (ED50 value AE 95% CL) of consumption was 14.8 (11.8e18.7) and 21.3 (18.5e24.4) mg/kg for the (þ) and (À) enantiomers, and there was a significant difference between the doseeeffect curves of (þ) and (À)-p-Cl-PAT (F 1,42 ¼ 10.2, p < 0.003).
Discussion
It is implicit from preclinical and clinical literature and practice that optimal 5HT2 pharmacology desired for antipsychotic drug efficacy without liability for weight-gain or other untoward side effects (such as cardiopulmonary toxicity associated with 5HT2B activation) is absolutely-selective 5HT2A antagonism and/or 5HT2C agonism. Accordingly, the unique multifunctional 5HT2 pharmacology (i.e., 5HT2A/2B antagonism together with 5HT2C agonism) demonstrated by (À)-(2S, 4R)-trans-PAT ) appears to be optimal for development of 5HT2-based antipsychotic drugs without weight gain and other deleterious side effects. Based on computational and molecular modeling structureeactivity studies, we predicted that the novel analog p-Cl-PAT would demonstrate 5HT2 pharmacology similar to PAT, i.e. (pre)clinical relevant affinity at 5HT2A and 5HT2C receptors but specifically activate only 5HT2C receptors. Unexpectedly, stereoselectivity regarding 5HT2 affinity and functional activity was reversed for pCl-PAT in comparison to PAT. Thus, the (þ)-(2R, 4S)-trans-p-Cl-PAT enantiomer had (pre)clinically-relevant high affinity across 5HT2 receptors, in comparison to the (À)-enantiomer, which had severalfold lower affinity. Likewise, functionally, the (þ)-p-Cl-PAT enantiomer was the more potent 5HT2C (partial) agonist. Importantly, however, (þ)-p-Cl-PAT did not activate 5HT2A or 5HT2B receptors (nor did the [e]-enantiomer) and was shown to competitively antagonize 5HT activation of 5HT2A-mediated activation of PLC and IP formation. These unexpected results concerning stereochemistry impact on 5HT2 ligand affinity and function provide important information for computational and modeling studies regarding the 3-dimensional arrangement of 5HT2 receptor amino acids in the binding pocket. Results will be used to refine current 5HT2 receptor models based on homology to the b-adrenergic receptors (CordovaSintjago et al., 2011 (CordovaSintjago et al., , 2012 for accurate prediction of ligand interactions for drug discovery purposes. Nevertheless, here we identified (þ)-p-Cl-PAT as a new high affinity 5HT2 receptor ligand that potently and specifically activates 5HT2C and not 5HT2A or 5HT2B receptors, precisely the 5HT2-based pharmacology desired for antipsychotic activity, without liability for 5HT2-mediated untoward side-effects such enhanced feeding behavior or cardiopulmonary toxicity.
To determine if the unique multifunctional 5HT2 receptor pharmacology of p-Cl-PAT would translate in vivo to preclinical antipsychotic activity, we examined their ability to modulate the DOI-elicited HTR in mice. DOI-elicited HTRs have been purported to model a number of behavioral and pathological conditions including schizophrenia/psychosis, obsessive-compulsive disorders, tics associated with Tourette's syndrome, and hallucinogenesis (Canal and Morgan, 2012) . Similarities in the subjective effects of psychedelic hallucinogens and the perceptual and subjective effects associated with psychosis-related disorders (e.g. schizophrenia) suggested that the behavioral effects following administration of hallucinogenic compounds (e.g. DOI-elicited HTRs) could be a model of the "positive" symptoms (in particular, hallucinations) of schizophrenia (González-Maeso et al., 2008) . In this regard, every effective antipsychotic medication used in humans is effective in attenuating the HTR elicited by DOI administration, including "typical" (primarily D2 antagonists) and "atypical" (5HT2/D2 antagonists) antipsychotics, as well as novel medications being investigated in clinical trials (e.g. glutamatergic compounds; clinicaltrials.gov). Although there are few "false negatives" associated with this model as a "screen" for antipsychotic activity, there are examples of "false positives" (i.e. drugs that work in the animal model and do not translate into effective antipsychotic compounds in humans). An important example is the relatively selective 5HT2A antagonist/inverse agonist M100907 which apparently failed in clinical trials for treating schizophrenia.
In fact, the in vitro 5HT2 molecular pharmacology of p-Cl-PAT translated congruently in vivo, with the (þ)-enantiomer being more potent than the (À)-enantiomer in the DOI-elicited HTR assay, and with the (þ/À)-racemic mixture being intermediate between the two in potency. It is proposed here that activation of 5HT2C receptors (5HT2A antagonism is implicit) associated with the lead (þ)-p-Cl-PAT analog may enhance its potential as an antipsychotic drug given that 5HT2C activation preferentially decreases mesolimbic dopamine levels while sparing nigrostriatal dopamine cell activity and extracellular levels (Di Giovanni et al., 2000) , a pharmacological profile suggesting antipsychotic effects without debilitating extrapyramidal side effects.
Another primary side effect of currently available antipsychotic medications is weight gain (Coccurello and Moles, 2010; Lieberman et al., 2005; Maayan and Correll, 2010; McCloughen and Foster, 2011) . In addition to the adverse health effects associated with weight gain itself (National Task Force on the Prevention and Treatment of Obesity, 2000), patient weight gain dramatically decreases antipsychotic medication compliance (Weiden et al., 2004) . There are conflicting data regarding the physiological mechanisms by which weight gain associated antipsychotic use occurs (Balt et al., 2011; Correll et al., 2011; Roerig et al., 2011) , however it has been suggested that antagonism of 5HT2C receptor systems may be partially responsible. For example, atypical antipsychotics generally have clinically-relevant affinity at several neurotransmitter receptor types, including, adrenergic (a1 and a2), dopamine (D1, D3 and D4), histamine (H1), muscarinic, and serotonin (5HT1A, 5HT2A, 5HT2C, 5HT6 and 5HT7). While 5HT2A receptor antagonism is thought to contribute to the efficacy of atypical antipsychotic drugs, most, such as olanzapine, also are about equi-potent at blocking 5HT2C receptors, which could contribute to their propensity to cause weight gain. In contrast, compounds that activate 5HT2C receptors are thought to enhance satiety, decrease meal size, and decrease caloric intake by stimulating pro-opiomelanocortin secretion from arcuate nucleus neurons (and subsequent activation of melanocortin systems) (Heisler et al., 2003; Hewitt et al., 2002) . Based on these and similar findings, there are drug discovery efforts toward a 5HT2C-specific agonist as a weight-loss medication (Halford et al., 2011) , but, for now, only a 5HT2C-preferring agonist (lorcaserin, Belviq) is available (Thomsen et al., 2008) .
Preliminary off-target binding studies with (þ)-and (À)-p-Cl-PAT have been undertaken and initial results suggest that, as for (À)-trans-PAT adenosine, adrenergic, benzodiazepine, cholinergic, dopamine, GABA A , histamine H 2 , H 3 , H 4 , NMDA/PCP, opiate, and serotonin 5-HT 1A , 5-HT 1B , receptors (PDSP, 2012) . Like (À)-trans-PAT, however, previous studies with racemic p-Cl-PAT indicate high affinity at histamine H1 GPCRs (Bucholtz et al., 1999) dthis is important because antagonist activity at the H1 GPCR correlates with atypical antipsychotic-induced weight gain (Kroeze et al., 2003) . Nevertheless, (À)-trans-PAT negatively modulates food intake in the mouse model of compulsive or binge eating (Robertson and Rowland, 2005; Rowland et al., 2008; Rowland, 2012) , and it was predicted that p-Cl-PAT also would decrease consumption of highly palatable "treats" based on the ability of p-Cl-PAT to activate 5HT2C receptors in vitro, similar to (À)-trans-PAT ). In the current studies, mice ate w40% of their daily caloric intake during a 30-min session, and both enantiomers of p-Cl-PAT decreased consumption. Consistent with the in vitro pharmacology, and, similar to the HTR studies, the (þ)-p-Cl-PAT enantiomer was more potent and effective than the (À)-isomer, and these effects occurred at doses similar to those that produced an "antipsychotic" effect. We propose that weight gain would not be a problem during chronic administration of (þ)-p-Cl-PAT as we have previously demonstrated that this acute effect on compulsive eating generalizes from acute to chronic protocols with (À)-trans-PAT .
In summary, the data presented here suggest that especially the (þ)-enantiomer of p-Cl-PAT shows promise for development as an orally effective antipsychotic medication that would not have liability for 5HT2-mediated weight gain or cardiovascular toxicities, and, likely would not demonstrate extrapyramidal motor side effects. Such an antipsychotic drug may help to overcome patient compliance issues commonly associated with adverse weight gain and motor side effects commonly observed with currently available antipsychotic drugs.
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